A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2014
Price : $35 *
At a glance
- Drugs Verinurad (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors Ardea Biosciences
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 May 2014 Planned End Date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record .